Yes, the scientist in me appreciates the continuous good science news. It is exciting to discover via post-hoc analyses that subgroups of patients in ASSERT, SUSTAIN and ASSURE are benefiting tremendously from RVX-208 in terms of not just cardiovascular disease but also diabetes and chronic kidney disease. The identification of RVX-208 high-responder groups such as low-HDL, high-CRP, and those with diabetes or kidney disease is great. The beneficial synergistic actions of RVX-208 with rosuvastatin (Crestor) moreso than with atorvastatin (Lipitor) was such a serendipitous and game changing discovery. It is also very exciting to see them using state of the art technologies such as microarray gene profiling to discover beneficial gene expression signatures, Emerald Logic FACET analysis to generate predictive models and reveal novel RVX-208-mediated variables/relationships, lipidomic analysis of the plasma HDL fraction to reveal more insight into how RVX-208 affects HDL composition/functionality. And the realization the MACE is tremendously impacted is huge.

However, at this point in the development of RVX-208, any more of simple science news on RVX-208 is all fluff. In my opinion, the biggest make or break event in the short term for Resverlogix is whether the FDA/EMA approves of a Phase III trial. We've heard lots about BETonMACE. However, its always the proposed BETonMACE trial. We still don't know for sure whether a Phase III trial is going to be allowed. Keep in mind that Phase II trial ASSURE failed. Only post-hoc analysis resurrected RVX-208. Sure, now hindsight is 20/20 in terms of proper patient populations (low-HDL, high-CRP, diabetes, CKD), statin interactions (crestor>lipitor), endpoints (MACE, alk phos), etc. But what if Phase III is not approved and another Phase II is required? How did those meetings with the EMA in April and FDA in May go? Could BETonMACE be relegated to a Phase II trial. If and when BETonMACE is officially announced as a Phase III trial, I think the flood gates will really open.

Also, when are these guys going to publish? Yes, they've presented talks and posters at various conferences. But when are they going to actually publish in peer reviewed journals. They are sitting on so much data, moreso that any of us retail shareholders realize. The last human clinical trial related RVX-208 publication is from April 2012 (http://www.ncbi.nlm.nih.gov/pubmed/22349989)and is just discussing the "rationale" for SUSTAIN and ASSURE. The last RVX-208 clinical trial publicaiton was on ASSERT in 2011 (http://www.ncbi.nlm.nih.gov/pubmed/21255957)Maybe they're sitting on this stuff for good reason, but with all the tidbits they've put out in piecemeal fashion, they could put together a pretty solid series of publications. Maybe they're waiting for the right moment? Maybe the peer review committee has major concerns? Who knows But they are long overdue for actual peer reviewed publications. They could attract a lot of interest into the stock/company with that kind of exposure.

And speaking of Zenith....what is the deal of what happened with ZEN-3365? Why does a publication come out with several Zenith co-authors (http://www.ncbi.nlm.nih.gov/pubmed/26022843)but the company doesn't even acknowledge it. What does this publication mean relative to ZEN-3365 or the two new next-generation compounds? Is this publication even relevant? Are all of the intellectual property findings of this paper irrelevant for the same mysterious reasons tha ZEN-3365 was abandoned? They're really dropping the ball on explaining this. But hey, they're a private company.....maybe they don't have to care what we think. Let's just hope they're true to their word that they are initiating phase I oncology clinical trials in H2 2015.

OK. Enough rant for now. June 30 special meeting can't come soon enough. Hoping for more clarity and answers then. Until then, anticipation and exciting will be countered by frustration and skepticism and who knows what the share price will do.

Best,

BDAZ